T HE MEDICARE PART D DRUG benefit was enacted as part of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 and was implemented in January 2006. Described as the "most significant improvement to senior health care in nearly 40 years," 1 the main purpose of the benefit is to reduce out-of-pocket expenditures and improve access to medications in seniors and other Medicare beneficiaries. Medicare Part D is delivered by numerous private insurance companies and involves beneficiaries choosing among many drug plans with premiums and benefit packages that vary considerably. The projected overall cost of the benefit is approximately $800 billion for 2004 through 2015. 2 In 2006, Medicare Part D accounted for 12% of total Medicare spending, with a per capita expenditure of $1742. 3 The implementation of Medicare Part D was driven by concerns that cost sharing for prescription medications was placing an increasing financial burden on seniors and by documented evidence that cost sharing has negative effects on adherence to therapy and health care utilization. For example, a recent systematic review found that increased cost sharing for prescription medications was associated with lower rates of drug treatment, worse adherence by existing users, and more frequent discontinuation of therapy. 4 These negative effects have been demonstrated in seniors, 5, 6 who are likely to be more vulnerable to the effects of cost sharing because they have more chronic conditions and lower-thanaverage household incomes than the general population. 7, 8 A few previous studies 9, 10 examined the effect of Part D on out-of-pocket expenditures and found reductions across all Medicare beneficiaries of 13.1% to 18.4%. However, these studies relied on dispensing data from selected pharmacy chains that may not be nationally representative and did not isolate the impact of Medicare Part D on the one-third of beneficiaries without previous drug coverage who are likely to benefit most from this policy. 11 A recently published study 12 found that the impact of the benefit on previously uninsured beneficiaries was positive, with 3% to 37% increases in drug use and 37% to 58% decreases in out-of-pocket expenditures, depending on drug class. However, this study had several limitations, including that the sample involved only patients who were continuous users of the same pharmacy chain, that changes in total out-of-pocket expenditures were not examined, and that enrollment status was assigned using an indirect method. There is also limited information on the impact of this policy on dual Medicare and Medicaid beneficiaries, who were required to switch to Medicare Part D from state-administered programs that may have had lower cost-sharing arrangements. 13 We used the Medical Expenditure Panel Survey (MEPS), which provides nationally representative estimates of health care use and expenditures, to evaluate the impact of the introduction of Medicare Part D on out-of-pocket expenditures on all medications. As part of this evaluation, we tested the hypothesis that Medicare beneficiaries without previous drug coverage who enroll in Part D will gain most from this benefit and that beneficiaries with previous drug coverage, such as dual Medicare and Medicaid beneficiaries, will not experience a change in out-of-pocket expenditures on medications. We also anticipated that Medicare beneficiaries without coverage before the introduction of Medicare Part D who did not enroll in it when it became available would not have a change in their out-ofpocket expenditures on medications.
METHODS
The MEPS is conducted to provide nationally representative estimates of health care use, expenditures, sources of payment, and insurance coverage for the US civilian noninstitutionalized population. The methods of the survey are described in detail elsewhere. 14, 15 In brief, we used the Household Component of the survey, which involves an overlapping panel design in which data are collected in a series of 6 rounds of faceto-face interviews. Data on medical expenditures and health care use for 2 calendar years are collected from each household. To overcome the problem of recall bias and potential underreporting associated with self-reporting, the MEPS obtains information on out-of-pocket expenditures directly from pharmacy providers rather than from respondents themselves. This process involves respondents authorizing the MEPS to contact their pharmacy provider and authorizing their pharmacy provider to release their records to the MEPS. Information about the amount and source of payment for medications is extracted from computerized printouts and written data forms provided by pharmacies. These data were imputed when this information was not provided by pharmacies. We applied survey weights in all the analyses to generate nationally representative findings. All the expenditures were converted to 2006 US dollars using the Medical Care Consumer Price Index to adjust for the 4% inflation rate during the study period. To account for the complex survey design and allow for population estimates of the US population, we used the SUDAAN statistical software package (RTI International, Research Triangle Park, North Carolina).
RESULTS
The overall response rate for the MEPS used in this study was 60. Table 1) . Respondents who enrolled in a Part D plan had lower educational attainment and were more likely to have a personal annual income of less than $25 000 compared with those who did not enroll. Individuals dually enrolled in Medicare and Medicaid were more likely to be female, to be from a nonwhite racial/ethnic group, and to have lower educational attainment and less personal income compared with those who did not enroll. They also had more chronic conditions than did those who did not enroll. Individuals who had drug coverage in both years were more likely to be male and to have higher educational attainment and personal income compared with those who did not enroll in Medicare Part D.
CHANGES IN TOTAL OUT-OF-POCKET EXPENDITURES ON MEDICATIONS
Mean out-of-pocket annual expenditures on all medications decreased by 32% ($320; 95% confidence interval (IQR, $188-$927) to $410 (IQR, $160-$878) in beneficiaries with coverage in both years. There were small increases in the use of antiglycemic agents, antidepressants, and respiratory inhalants between 2005 and 2006 in all Medicare beneficiaries participating in the MEPS, but these increases were statistically significant only for antiglycemic agents. There were small but nonsignificant increases in the use of statins, ␤-blockers, antiglycemic agents and antidepressants between 2005 and 2006 in beneficiaries without previous drug coverage who enrolled in Medicare Part D. Utilization increased for antiglycemic agents and antidepressants in beneficiaries without previous drug coverage who did not enroll in Part D, but these changes were statistically significant only for antiglycemic agents. There were small increases in the use of antiglycemic agents, antidepressants, and respiratory inhalants between 2005 and 2006 in beneficiaries with drug coverage in both years, but these increases were statistically significant only for antiglycemic agents.
CHANGES IN UTILIZATION AND OUT-OF-POCKET EXPENDITURES ON COMMONLY PRESCRIBED MEDICATIONS

COMMENT
Although the introduction of Medicare Part D was associated with reductions in out-of-pocket expenditures on medications overall, the impact of this benefit varied considerably among the different groups of Medicare beneficiaries studied. As would be expected in a voluntary program, the magnitude of the reduction was greater in beneficiaries without previous drug coverage who enrolled in Part D than in beneficiaries who did not enroll. The difference in these 2 groups may be explained by differences in health-related selection. However, the finding that those who did not enroll also experienced a reduction in their out-of-pocket expenses across time reflects the secular trend and suggests that the net effect of this program may have been modest.
The estimate of the reduction in out-of-pocket expenditures across all older Medicare beneficiaries in the MEPS of 32% is higher than that reported previously (13%-18%). 9, 10 Previous studies may have underestimated the benefits of Part D because they were based on 1.3) 13.1 (0.8) 8.9 (1.5) b 10.6 (1.4) b 12.6 (1.6) 12.3 (1.1) 9.6 (1.0) data from a single pharmacy chain and may have captured a younger, urban-dwelling group than is typical for Medicare beneficiaries, including fewer beneficiaries without previous drug coverage. For example, a related study by Schneeweiss et al 12 found that only 14% of elderly Medicare beneficiaries receiving their drugs from pharmacies had no drug coverage in 2005. This figure is considerably below the 1 in 3 estimate published in previous studies and by the Centers for Medicare & Medicaid Services. 16 We did not identify a significant change in out-ofpocket expenditures on medications in dual Medicare and Medicaid beneficiaries, suggesting that the transition of responsibility for drug coverage from the states to the federal government did not have an adverse financial consequence on this group. However, note that dual beneficiaries and Medicare beneficiaries with other drug coverage in 2005 and 2006 did not benefit from the same reductions in outof-pocket expenditures experienced by beneficiaries without insurance during the study period. A previous study 17 that used data from a single pharmacy chain found that the introduction of Medicare Part D was associated with small reductions in out-of-pocket expenditures on clopidogrel, proton pump inhibitors, warfarin, and statins but with increases in out-of-pocket expenditures on benzodiazepines in dual Medicare and Medicaid beneficiaries.
Half of the Medicare beneficiaries who were without drug coverage in 2005 enrolled in a Part D plan. This finding is consistent with that of a previous study. 12 Although we did not identify any differences in health status between beneficiaries without previous coverage who enrolled in Part D and those who did not, the group who enrolled in Part D had higher baseline out-of-pocket expenditures on medications. This may suggest that Medicare beneficiaries with low out-of-pocket expenditures on medications are uncertain about how they will personally benefit from this program. Two-thirds of those who did not enroll in a Part D plan had an annual household income of less $25 000. This finding suggests that additional efforts may be required to improve enrollment in the benefit's low-income subsidy scheme, which provides premium and cost-sharing assistance. Recent data suggest that 63% of beneficiaries who are entitled to the low-income subsidy and who are not automatically enrolled have not received this. 18 The present study has several strengths and limitations. The MEPS provides nationally representative estimates of health care use, expenditures, sources of payment, and insurance coverage and contains detailed information about the type, frequency, and cost of prescription medications. The precision of national estimates of medical expenditures became a priority and data collection procedures have been improved during the past decade to increase the overall accuracy of these measures. 19 Nevertheless, the percentage of Medicare beneficiaries participating in the MEPS who were without drug coverage before the introduction of Part D was higher than estimates for the general Medicare population (44% vs 33%). 16 The response rate for the MEPS is modest (60%), and information about out-of-pocket expenditures was unavailable or not complete in some respondents owing to nonresponse by some pharmacy providers. 15 Because the MEPS is a panel survey, we used a longitudinal study design, which overcomes the bias inherent in comparing crosssectional surveys involving respondents who may systematically differ. The study design meant that we excluded approximately 50% of Medicare beneficiaries who participated in the MEPS during the study period. We assigned beneficiaries to 1 of 4 groups on the basis of their drug coverage status in the last month of 2005 and 2006. Although this may not reflect their coverage status for the entire year, this approach ensured that we could examine the impact of Part D in beneficiaries who enrolled in this benefit during and after the penalty-free period in 2006 ( January-May). Some of the comparisons of expenditures and medicine use may not have reached statistical significance due to the small numbers in the subgroups. Furthermore, estimates for utilization and out-of-pocket expenditures on antiglycemics, antidepressants, and respiratory inhalants in all the groups and all individual drug class estimates in dual beneficiaries should be treated with caution because they are based on samples of fewer than 100. Although the MEPS includes questions about costrelated nonadherence, the sample size was too small to examine whether this changed during the study period. The data used for this study are 4 years old, and these findings may not reflect the current impact of Medicare Part D on out-of-pocket expenditures on medications. We examined the aggregate effects of this policy by insurance status, which may not reflect the experiences of individual beneficiaries, some of whom may have experienced an increase in out-of-pocket expenditures after the introduction of Part D (eg, an uninsured individual who did not fill a needed prescription for a medication but does so after enrolling in Part D because he or she decides that the co-pay is "worth it"). This study focused on the impact of this policy on seniors rather than on all beneficiaries. Owing to the small sample size, we could not examine the effects of Part D in additional drug classes or the contribution of the coverage gap ("doughnut hole"), where beneficiaries are required to meet all prescriptions costs after they have reached a threshold of $2700 in a given year before catastrophic coverage begins at $6154, to out-of-pocket expenditures. Whereas early studies indicated that the percentage of beneficiaries reaching this threshold was small, 20, 21 more recent data from 2007 suggest that 14% of all Part D enrollees are affected by this coverage gap. 22 Medicare Part D has considerable potential to improve senior health and reduce overall health care expenditures by increasing uptake of effective secondary prevention interventions. 23 Key to this is reducing out-ofpocket expenditures and associated cost-related nonadherence. Although the implication of these findings is that Medicare Part D has achieved some of its intended effect of reducing Medicare beneficiaries' out-of-pocket expenditures on medications, a question remains about whether the financial gain derived by beneficiaries is sufficient given the high public cost of the program. This is highlighted by the considerable gap between the reduction in out-ofpocket expenditures experienced by all Medicare beneficiaries in this study and the per capita investment in this program in 2006 ($320 vs $1742). Moreover, this figure may overestimate the impact of Medicare Part D on outof-pocket expenditures for 2 reasons. First, out-ofpocket expenditures on medications decreased by a simi-lar amount ($353) in beneficiaries who did not enroll in Part D. This finding is consistent with those of previous studies that have found reductions in out-of-pocket expenditures on medications during this period and suggests that part of this decrease may be attributable to other factors, including the increased availability and use of generic drugs and the introduction of discount prices by large supermarket chains. 24 Second, this evaluation does not consider beneficiary expenditures on Part D premiums, data which are unavailable in the MEPs. Although we could not examine the impact of Medicare Part D on costrelated nonadherence, previous research 25 suggests that the percentage of Medicare beneficiaries reporting not taking medications owing to cost declined only marginally during the first year of this benefit.
Future research should examine the longer-term impact of Medicare Part D on medication use, health care utilization, cost, and health outcomes and the extent to which vulnerable groups, including those with low income and racial/ethnic minorities, who report higher levels of cost-related nonadherence, are benefiting. 26 In conclusion, the introduction of Medicare Part D was associated with reductions in Medicare beneficiaries' outof-pocket expenditures on medications, particularly in beneficiaries without previous drug coverage. Although this insurance program may have improved the protection of seniors from large financial risk, associated reductions in out-of-pocket expenditures were modest and a question remains about whether the financial benefit for beneficiaries is adequate given the high public cost of providing pharmacy coverage through Medicare. The provision of direct consumer subsidies for medications may prove more cost-effective in reducing out-of-pocket expenditures in seniors than the current market-based approach.
